Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Apply filters
Showing 151 to 200 of 392
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]
Technology appraisal guidance
TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238
Technology appraisal guidance
TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237
Technology appraisal guidance
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Technology appraisal guidance
TBC
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome
Diagnostics guidance
19 December 2024
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]
Technology appraisal guidance
30 April 2025
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
Technology appraisal guidance
TBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]
Technology appraisal guidance
23 April 2025
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Technology appraisal guidance
TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]
Technology appraisal guidance
TBC
Implanting a baroreceptor stimulation device for resistant hypertension
Interventional procedures guidance
TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]
Technology appraisal guidance
TBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459
Technology appraisal guidance
TBC
Insertion of neo-chordae into the beating heart for mitral regurgitation
Interventional procedures guidance
TBC
Insulin icodec for treating type 2 diabetes [ID6175]
Technology appraisal guidance
TBC
Intermittent urethral catheters for urinary management in adults : Late Stage Assessment
Health technology evaluation
TBC
Intrapartum Care - maternal hyponatremia
NICE guideline
26 March 2025
Intrapartum care - uterotonics for postpartum haemorrhage
NICE guideline
3 December 2024
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention
Interventional procedures guidance
5 February 2025
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Technology appraisal guidance
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Technology appraisal guidance
TBC
Iptacopan for treating complement 3 glomerulopathy ID6283
Technology appraisal guidance
TBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981
Technology appraisal guidance
16 July 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
Technology appraisal guidance
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Technology appraisal guidance
TBC
Kidney Cancer
NICE guideline
TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]
Technology appraisal guidance
TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
Technology appraisal guidance
TBC
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease
Interventional procedures guidance
17 April 2025
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]
Technology appraisal guidance
5 February 2025
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Technology appraisal guidance
TBC
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]
Highly specialised technology
5 March 2025
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Technology appraisal guidance
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Technology appraisal guidance
TBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]
Technology appraisal guidance
TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]
Technology appraisal guidance
TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Technology appraisal guidance
TBC
Linzagolix for treating symptoms of endometriosis [ID6357]
Technology appraisal guidance
25 June 2025
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]
Technology appraisal guidance
TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]
Technology appraisal guidance
TBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Technology appraisal guidance
TBC
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]
Technology appraisal guidance
30 April 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Technology appraisal guidance
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Technology appraisal guidance
TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
Technology appraisal guidance
TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]
Technology appraisal guidance
TBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)
NICE guideline
TBC
Managing common infections - antimicrobial prescribing guidelines
NICE guideline
TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
Technology appraisal guidance
22 January 2025
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
Technology appraisal guidance
TBC
Previous page
1
2
3
Current page
4
5
6
…
8
Page
4
of
8
Next page
Results per page
10
25
50
All
Back to top